MVA of prognostic factors in LBCL treated with anti-CD19 CAR T cells
| . | PFS . | OS . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P∗ . | HR . | 95% CI . | P∗ . | |
| ECOG PS, ≥2 (vs < 2) | — | — | — | 1.19 | 0.43-3.30 | .73 |
| Stage, III-IV (vs I-II) | 0.97 | 0.45-2.08 | >.90 | — | — | — |
| Lines of therapy before leukapheresis, ≥4 (vs <4) | — | — | — | 2.26 | 0.88-5.75 | .09 |
| LDH, U/L, >ULN (vs ≤ ULN) | 2.30 | 1.11-4.74 | .025 | 2.43 | 0.78-7.59 | .13 |
| CRP, mg/mL, >30 (vs ≤ 30) | — | — | — | 1.32 | 0.53-3.27 | .55 |
| Ferritin, μg/L, >1000 (vs <1000) | — | — | — | 1.74 | 0.64-4.74 | .28 |
| mHLA-DR D−7, Ab/c, <13 500 (vs > 13 500) | 2.04 | .92-4.55 | .079 | 3.37 | 1.16-9.77 | .03 |
| CAR T cell type, tisa-cel (vs axi-cel) | 2.55 | 1.37-4.76 | .003 | — | — | — |
| . | PFS . | OS . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P∗ . | HR . | 95% CI . | P∗ . | |
| ECOG PS, ≥2 (vs < 2) | — | — | — | 1.19 | 0.43-3.30 | .73 |
| Stage, III-IV (vs I-II) | 0.97 | 0.45-2.08 | >.90 | — | — | — |
| Lines of therapy before leukapheresis, ≥4 (vs <4) | — | — | — | 2.26 | 0.88-5.75 | .09 |
| LDH, U/L, >ULN (vs ≤ ULN) | 2.30 | 1.11-4.74 | .025 | 2.43 | 0.78-7.59 | .13 |
| CRP, mg/mL, >30 (vs ≤ 30) | — | — | — | 1.32 | 0.53-3.27 | .55 |
| Ferritin, μg/L, >1000 (vs <1000) | — | — | — | 1.74 | 0.64-4.74 | .28 |
| mHLA-DR D−7, Ab/c, <13 500 (vs > 13 500) | 2.04 | .92-4.55 | .079 | 3.37 | 1.16-9.77 | .03 |
| CAR T cell type, tisa-cel (vs axi-cel) | 2.55 | 1.37-4.76 | .003 | — | — | — |
F, female; M, male; ULN, upper limit of normal.
Bold indicates statistical significance.